What Lonza’s three-month tox supply and six-month IND claim actually covers
Wholesale Peptide Wholesale Enkephalin The claim is narrower than the headline. The accelerated biologics timeline rests on a specific material choice and a specific starting point, and both are footnoted on the pages that carry the numbers.
The bispecific programme page states “3 months to tox material supply” and “DNA to IND in as little as 6 Monate,” with the six-month footnote reading “Based on the use of pool material. From DNA transfection to delivery of IND-enabling CMC modules. Typical timelines. Subject to agreement with regulatory authorities” (the bispecific programme page). The same page offers an eight-month pathway footnoted “Based on the use of clonal material,” so the faster number depends on earlier-stage pool material rather than a clonal line (the clonal-material alternative).
The mAb programme carries the same structure at shorter intervals: “2 months to tox drug substance,” “3 months to tox drug product,” and DNA-to-IND in as little as 6 months on pool material, with an 8-month alternative on clonal material (Lonza’s mAb programme). The overview page adds an eligibility qualifier, describing toxicology drug substance “available as early as two months for eligible programs” (the DNA-to-IND programme overview).
Lonza’s own account of how the acceleration works is parallel execution rather than calendar compression: early analytical development, process development “built for robustness and scalability,” and regulatory readiness designed in from the outset (Lonza’s own account of how the acceleration works). Lonza’s six-month explainer frames the choice between six and eight months as a function of the molecule and development goal (Lonza’s six-month explainer).
The qualifier moves the number by 33%. A buyer who quotes six months without the pool-material footnote is quoting a different program than the one described.
Why a biologics platform timeline cannot be copied onto a peptide program
The same review reports production-scale SPPS reactors from hundreds of litres up to a 6000 L system, with peptides around 70 residues feasible in principle, and notes that inefficient coupling, low yield and excessive impurity formation are sometimes tied to secondary structure of the protected peptide on the resin. It also puts the practical length limit of SPPS at approximately 100 Aminosäuren, because iterative synthesis “potentially generates a large number of impurities (e.g., deletion and truncation), with a chemical structure close to that of” the target (the practical length limit of SPPS).
Some sequences fail for structural reasons rather than length. The peptide literature’s definition of a difficult sequence covers peptides prone to intra- and interchain secondary structures, with hindered Fmoc removal and acylation and truncated or gapped byproducts that are difficult to separate from the target; aggregation-prone motifs include runs of β-methyl residues, alternating hydrophobic and bulky residues, and high glycine content (the peptide literature’s definition of a difficult sequence).
Purity data alone will not reveal all of it. In difficult-sequence syntheses, byproducts lacking internal residues, truncated peptides and Fmoc-retaining peptides were detectable only by ESI-MS/MS and MALDI-TOF, and several sequences yielded only trace target under a standard schedule (MS/MS detection of sequence-related byproducts).
The arithmetic is the argument. At 99.0% per-step success, a 40-residue chain leaves roughly two-thirds of the material full-length before purification; bei 99.8%, roughly nine-tenths at 50 Rückstände. A platform calendar cannot predict where a given sequence lands on that curve, which is why peptide synthesis scale decisions rest on measured coupling performance.
What sequence confirmation must prove before downstream data is trusted
Sequence confirmation is the gate that validates every later number. If identity is not established by more than one method, a purity figure describes an unknown substance.
The EMA’s synthetic-peptide guideline requires that “the structure of the peptide should be confirmed by analytical data,” including primary and, where relevant, higher-order structure, and recommends at least two orthogonal methods for identification at release, with mass, relative Retentionszeit, LC-MS, Peptidkartierung, amino acid analysis or NMR all considered appropriate (the EMA’s synthetic-peptide guideline). The applicant must show the chosen combination unambiguously confirms the sequence.
ICH Q6B’s structure-confirmation logic sets the same expectation for sequence determination “to the extent possible,” listing amino acid composition, terminal sequence analysis, peptide mapping by HPLC and mass spectrometry, with validated peptide mapping “frequently used to confirm desired product structure for lot release purposes” (ICH Q6B’s structure-confirmation logic). Q6B also notes that synthetic peptides fall outside its scope, so the EMA document is the more specific authority for a chemically synthesized molecule.
Neither document supplies a numeric identity threshold, because ICH Q6B’s definition of a specification makes acceptance criteria “proposed and justified by the manufacturer and approved by regulatory authorities,” with purity acknowledged as method-dependent (ICH Q6B’s definition of a specification).
Reinheit, Identität, content and assay answer four different questions. A single HPLC percentage is a purity figure. Identity needs orthogonal confirmation, Inhalt oder Nettopeptid Mans Peptide requires its own determination, and assay suitability depends on a reference standard. A proposal that offers one certificate number as proof of all four has answered one question.
The evidence request is concrete: the sequence version under test, the orthogonal pair used at release, and the lot-level data showing both methods agree.
What a defensible impurity profile contains at toxicology stage
Peptide impurity profiling runs on thresholds that differ from the small-molecule defaults, and the difference is large enough to change a specification.
The EMA’s synthetic-peptide guideline, in force since June 2026, states that synthetic peptides are fully or partially excluded from ICH Q3A/B and that, per the Ph. Eur. general monograph “Substances for Pharmaceutical Use” (2034), peptide-related impurities should be reported above 0.1%, identified above 0.5% and qualified above 1.0% (the EMA’s synthetic-peptide guideline, in force since June 2026). Where co-eluting impurities appear as one peak, Die 1.0% qualification threshold applies unless otherwise justified.
ICH Q3A(R2) sets the small-molecule defaults at 0.05% Berichterstattung, 0.10% identification and 0.15% qualification for a maximum daily dose up to 2 g/day, and its preamble lists peptide products among those not covered (ICH Q3A(R2)). Applying those numbers to a peptide is a scope error in the buyer’s favor, since they are tighter than the peptide thresholds.
The EMA guideline’s impurity taxonomy separates peptide-related impurities, which are structural elements of the sequence, from non-peptide impurities such as process reagents, residual solvents and elemental impurities. Peptide-related sources include starting-material defects (incorrect enantiomers and diastereomers, wrong amino acids, β-Ala residues, dipeptides) and process formation (epimerisation stereoisomers, deletion sequences, truncations from capping) (the EMA guideline’s impurity taxonomy).
A profile is only as good as the method behind it. ICH Q2(R2)’s validation characteristics require a quantitative HPLC purity or impurity procedure to address specificity and selectivity, including spiking with known impurities or orthogonal comparison and forced degradation where needed, a calibration model with at least five points plus quantitation and detection limits, Genauigkeit, repeatability, intermediate precision and robustness, and the guideline sets no universal numeric acceptance criteria (ICH Q2(R2)’s validation characteristics).
Co-eluting peaks hide the impurity you most need to see. When two peptide-related impurities resolve as one peak, the EMA guideline applies the 1.0% qualification threshold to the combination unless justified. Ask which peaks in the profile are unresolved combinations and what orthogonal method was used to characterize them.
FDA withdrew its May 2021 general synthetic-peptide ANDA guidance in July 2026. Evaluate current relevant product-specific Peptide Factory Manufacturer drafts or final guidance and their status; historical 0.10%/0.5% criteria are not universal current limits.
What evidence shows a peptide process is scalable, not just reproducible at one scale
Peptide scale-up from mg to kg is proven by a scale-effect study, not by a successful small-batch run. The distinction matters because a process that works at 0.1 mmol tells you nothing about a 6000 L reactor.
ICH Q11’s position on scale effects is that a small-scale model “should account for scale effects and be representative of the proposed commercial process,” that scaling factors should be included for steps intended to span multiple operational scales when the step is scale dependent, and that small-scale data can reduce reliance on commercial-scale validation batches only once the model is shown scalable (ICH Q11’s position on scale effects).
Two published campaigns show what real production-scale peptide data look like. A published kilogram-scale tirzepatide campaign, a 39-residue peptide made by hybrid SPPS/LPPS with continuous manufacturing, reported approximately 81% overall activity yield with 8.71 kg isolated and crude purity around 90% by HPLC (a published kilogram-scale tirzepatide campaign). A matched small- versus production-scale comparison of liraglutide at 0.1 mmol and 25 mmol in a 3 L vessel gave 77–78% crude purity at production scale, matching wash-based results at research and production scale, with model crude purities around 75–84% (a matched small- versus production-scale comparison).
Per-step stereochemical fidelity does not by itself establish total epimer content in the isolated peptide. Measure relevant stereoisomeric impurities and distinguish analytical thresholds from product-specific acceptance criteria. Peptide Research
Request the scale-effect study, not the scale-up promise. The document to ask for is a comparison of at least two operational scales of the same process, with scaling factors stated for each scale-dependent step and impurity profiles compared side by side. A single-scale batch record does not answer the question ICH Q11 poses.
No published source quantifies a typical purity loss from mg to kg for peptides, so treat any proposal that offers one as unsupported until the underlying data is shown.
How we apply this at MOL Changes, the publisher of this guide. Our peptide synthesis work spans milligram to kilogram quantities, which is the range a scale-effect study has to bridge. What that does not give you is a validated scale-effect package or GMP clinical supply; you still have to request the per-scale data and judge it yourself, with any supplier, ours included.
Which release tests and records are non-negotiable, and what a CoA must carry
Release timelines depend on required tests and validated methods. Compendial sterility testing commonly uses a minimum 14-day incubation where applicable, but not every peptide lot requires sterility testing, and justified alternative methods may have different timelines.
The records layer is where proposals most often thin out. The audit-trail requirement in 21 CFR 11.10(e) calls for “secure, computergeneriert, time-stamped audit trails” that record operator entries and actions creating, modifying or deleting electronic records, with changes not obscuring previously recorded information and the trail retained at least as long as the subject records and available for agency review (the audit-trail requirement in 21 CFR 11.10(e)). MHRA’s ALCOA expectations define data as attributable, lesbar, gleichzeitig, originell und genau, with complete, konsistent, enduring and available added, and require that audit trails identified by risk assessment be switched on, that users cannot amend or disable them, and that an administrator override itself be recorded (MHRA’s ALCOA expectations). Peptide Factory Supplier
The IND CMC requirement in 21 CFR 312.23(A)(7) sets what the package must ultimately support: sufficient information “to assure the proper identification, quality, Reinheit, and strength of the investigational drug,” with emphasis in an initial Phase 1 submission on identification and control of raw materials and the new drug substance, final specifications not expected until the end of investigation, and information amendments required as scale changes from pilot to larger scale (the IND CMC requirement in 21 CFR 312.23(A)(7)).
A connected data package, not a certificate. The CoA should carry the sequence version tested, any modification site, the counterion form, the method identifier behind each result, and the lot number, and it should be traceable to the chromatograms and mass spectra that produced it. A summary certificate without the underlying records cannot be reconstructed, and MHRA’s guidance states that paper copies of dynamic electronic data cannot be considered raw data.
How peptide CRO selection turns a proposal into per-gate evidence requests
Peptide CRO selection reduces to one test: for each gate, does the proposal carry evidence you can inspect, or only a number you can quote? The four gates give you a fixed set of questions that applies to any supplier.
|
Tor |
Evidence to request |
Standard it answers to |
|---|---|---|
|
Sequenzbestätigung |
Sequence version under test, two orthogonal identification methods, lot-level agreement between them |
EMA-Richtlinie für synthetische Peptide; ICH Q6B |
|
Impurity profiling |
Peptide-related impurity list with thresholds applied, unresolved-peak treatment, validated method with forced degradation |
EMA-Richtlinie (0.1/0.5/1.0%); ICH Q2(R2) |
|
Scale-up |
Two-scale comparison of the same process, scaling factors for scale-dependent steps, impurity profiles at both scales |
ICH Q11 |
|
Release testing |
USP 〈71〉 and 〈85〉 protocols with incubation and inhibition/enhancement data, audit trails enabled, raw data retrievable |
USP 〈71〉/〈85〉; 21 CFR Teil 11; MHRA ALCOA |
Three implications follow for different readers. A sponsor buyer should treat a missing gate as a schedule risk, not a documentation gap, because each gate that fails late costs more than the time it saved. A CRO should expect the request and prepare the two-scale comparison before the proposal stage. A filing reviewer should read the impurity section for the thresholds actually applied, since a peptide dossier built on Q3A numbers has mis-scoped its specification.
The decision rule is single and quotable: if any one of the four gates is missing from the proposal and the supplier will not commit to supplying the evidence before contract signature, the timeline is not a commitment and should not enter your filing plan.
Abschluss
Lonza’s three-month tox-supply and six-month IND figures are real, footnoted and specific to a biologics platform operating on pool material with a defined starting point. They do not describe a peptide program, and the peptide literature explains why: sub-100% per-coupling yield, sequence-dependent aggregation, and byproducts that HPLC alone will not reveal.
The four gates hold regardless of which supplier you are evaluating. Sequence confirmation must be orthogonal and lot-level. Impurity profiling must apply the peptide thresholds of 0.1% Berichterstattung, 0.5% identification and 1.0% qualification, with unresolved peaks treated as combinations. Scale-up must rest on a two-scale comparison with stated scaling factors. Release testing must carry the 14-day sterility incubation, the endotoxin inhibition/enhancement data, and audit trails that satisfy 21 CFR 11.10(e) and MHRA ALCOA.
The earned takeaway is that speed and readiness are different claims, and only one of them is transferable between modalities. The next step is to take the proposal in front of you and mark which of the four gates it answers with evidence you can open. Where a gate is blank, that is the question to send back before signature.
Publisher disclosure: MOL Changes supplies peptide services and has a commercial interest in this topic. Service ranges and capability statements are supplier claims; availability and performance for a specific construct require project-specific evidence.
